Q1 Earnings Estimate for GT Biopharma Issued By Roth Capital

GT Biopharma, Inc. (NASDAQ:GTBP) – Roth Capital dropped their Q1 2025 earnings per share (EPS) estimates for GT Biopharma in a research report issued to clients and investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($0.64) for the quarter, down from their previous forecast of ($0.59). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for GT Biopharma’s current full-year earnings is ($6.79) per share. Roth Capital also issued estimates for GT Biopharma’s Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.29) EPS, FY2026 earnings at ($1.83) EPS, FY2027 earnings at ($1.57) EPS and FY2028 earnings at ($1.35) EPS.

Separately, Roth Mkm began coverage on shares of GT Biopharma in a report on Monday, December 2nd. They issued a “buy” rating and a $11.00 price objective for the company.

GT Biopharma Stock Down 2.5 %

NASDAQ:GTBP opened at $2.30 on Friday. The company has a 50 day moving average price of $2.43 and a 200-day moving average price of $2.47. GT Biopharma has a 1-year low of $1.72 and a 1-year high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.